Welcome to our dedicated page for KAIROS PHARMA news (Ticker: KAPA), a resource for investors and traders seeking the latest updates and insights on KAIROS PHARMA stock.
Kairos Pharma Ltd (NYSE American: KAPA) is a clinical-stage biopharmaceutical company advancing precision oncology therapies targeting complex challenges like drug resistance. This page aggregates official press releases, clinical trial developments, and strategic partnership announcements to keep stakeholders informed.
Investors and researchers will find timely updates on KAPA's investigational therapies, biomarker validation progress, and regulatory milestones. Content spans clinical trial results, FDA submissions, and diagnostic partnership developments, providing a comprehensive view of the company's scientific trajectory.
All materials are sourced directly from verified company communications, ensuring accuracy for those monitoring advancements in personalized cancer treatments. Bookmark this page for streamlined access to KAPA's latest innovations in structural biology-driven therapeutics and companion diagnostic research.
Kairos Pharma (NYSE: KAPA) provided a stockholder update highlighting its clinical progress and future outlook. The company is conducting two clinical trials for its lead drug ENV105: a Phase 2 trial for prostate cancer and a Phase 1 trial for EGFR-dependent non-small cell lung cancer. The company received an $876,000 Department of Defense grant for biomarker studies.
Trial sites have expanded beyond Cedars Sinai Hospital to include the University of Utah and City of Hope, with safety and interim efficacy results expected by Q2 2025. The company is also developing KROS101, a GITR ligand small molecule agonist for cancer treatment, with data presented at multiple scientific conferences.
The company maintains a strong financial position through recent private placement and non-dilutive funding, with research coverage from multiple investment banks including EF Hutton and HC Wainwright.
Kairos Pharma (NYSE American: KAPA) has received a $876,000 Department of Defense grant to support research identifying biomarkers in non-small cell lung cancer patients who develop resistance to osimertinib treatment. The grant was awarded to Cedars-Sinai Medical Center to support research in Dr. Neil Bhowmick's laboratory.
The company is currently conducting a Phase 1 trial of its lead compound ENV105 in combination with osimertinib for EGFR-driven lung cancer patients who fail to respond to single-agent osimertinib. The funded research aims to develop strategies for early detection of drug resistance and identify patients who would benefit most from ENV105 treatment, potentially improving overall survival and quality of life for patients.
Kairos Pharma (NYSE: KAPA) has completed the safety lead-in phase of its Phase 2 clinical trial for ENV105 in treating metastatic, castration-resistant prostate cancer. The trial combines ENV105 with apalutamide, a standard prostate cancer treatment.
The study consists of two parts: the completed safety lead-in and an ongoing randomized portion comparing apalutamide alone versus apalutamide with ENV105. The company expects to release safety and efficacy data from the safety arm in the first half of 2025.
Patient enrollment continues for the randomization arm at cancer centers in Los Angeles and Salt Lake City. The trial includes biomarker validation to identify patients most likely to benefit from the combination therapy. The study is supported by Kairos Pharma and a National Cancer Institute grant.
CEO.CA, a leading investor social network for venture stocks, has released an exclusive interview with John Yu, CEO & Chairman of Kairos Pharma (NYSE: KAPA), discussing their cancer treatment ENV105. The interview, part of CEO.CA's 'Inside the Boardroom' series, focuses on the company's recent funding and its impact on research acceleration.
The interview is available on CEO.CA's platform and YouTube channel, which serves millions of visitors annually as one of Canada's most popular financial websites. The platform, founded in 2012 and now a subsidiary of EarthLabs, Inc., offers investors worldwide a space to connect, share knowledge, and access information about stocks, commodities, and emerging companies.
Kairos Pharma (NYSE American: KAPA), a clinical-stage biopharmaceutical company, has announced its participation in several key scientific and industry events. The company presented their novel GITR Agonist KROS 101 research at the Society for Immunotherapy of Cancer Spring Scientific Meeting on March 12, 2025, and attended the BIO Europe conference in Milan.
Upcoming events include participation in the Fierce Pharma Engage Business Development meeting in San Diego (April 29-May 1) and a presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago (May 20-June 5). The company recently received research coverage initiation from Maxim Group on March 27.
CEO John Yu highlighted that Phase 2 trials for ENV105 are advancing, while their KROS platform shows promise in cancer immunotherapy, demonstrating the company's commitment to oncology program development and shareholder value creation.
Kairos Pharma (NYSE American: KAPA) has published peer-reviewed research revealing a potential breakthrough in treating drug resistance in non-small cell lung cancer (NSCLC). The study, published in Drug Resistance Updates, demonstrates that CD105 (endoglin) plays a important role in resistance to osimertinib, a frontline NSCLC treatment.
The research shows that ENV105 (carotuximab), a CD105-neutralizing antibody, successfully restored treatment sensitivity to EGFR-targeted therapies in preclinical models. The combination of osimertinib with ENV105 reinstated susceptibility to EGFR inhibition through metabolic reprogramming and enhanced chromatin accessibility.
The global NSCLC treatment market is projected to reach $45 billion by 2030. Kairos Pharma is currently conducting clinical trials to evaluate this therapy in EGFR-driven lung cancer patients.
Kairos Pharma (NYSE: KAPA) presented preclinical data on two investigational compounds at the AACR IO conference in Los Angeles (Feb 23-26, 2025). The first compound, KROS 101, a GITR agonist, showed significant tumor growth inhibition in melanoma models and demonstrated superior anti-tumor activity compared to TRX518. It increased helper and cytotoxic T cell proliferation while preventing T cell exhaustion in tumors.
The second compound, KROS 401, a peptide inhibitor, showed promise in reprogramming macrophages to inhibit tumor growth. Studies revealed anti-tumor effects in glioma-bearing mice by decreasing M2 macrophages that typically facilitate tumor growth. The research indicates potential therapeutic applications for both melanoma and glioblastoma treatment.
Kairos Pharma (NYSE American: KAPA) announces that its academic partner Cedars-Sinai Medical Center has received $600,000 in funding from the Department of Defense Lung Cancer Research Program to advance the development of ENV205.
ENV205 is a first-in-class therapy designed to reverse chemotherapy drug resistance, counteract muscle loss, improve strength, and enhance the effectiveness of existing cancer treatments. The drug targets key pathways driving cachexia, a severe muscle-wasting condition affecting over half of cancer patients, characterized by involuntary weight loss, muscle atrophy, and systemic inflammation.
The funding will accelerate research efforts through the company's ongoing partnership with Cedars-Sinai Medical Center, aiming to advance the therapy toward clinical trials.
Kairos Pharma (NYSE American: KAPA) announces the addition of Huntsman Cancer Institute in Salt Lake City, Utah as a new site for its Phase 2 clinical trial of ENV105 in castrate-resistant prostate cancer patients. The randomized trial compares apalutamide alone versus apalutamide+ENV105 combination therapy. The study, supported by Kairos and the National Cancer Institute, aims to identify blood markers that could help select patients who would benefit most from ENV105 treatment.
ENV105 is being developed to address resistance in various cancers as they become resistant to standard treatments. The addition of Huntsman, a renowned cancer center, is expected to enable testing ENV105 in a broader patient population while adding credibility to the study within the medical community.
Kairos Pharma (NYSE American: KAPA) presented preclinical data on its GITR agonist, KROS101, at the AACR-JCA Joint Conference. The research demonstrated KROS101's effectiveness in enhancing T cell infiltration, proliferation, and cancer cell-killing abilities in melanoma mouse models and human glioblastoma in vitro.
The compound showed significant results in reducing melanoma tumors in human GITR knock-in mouse models, outperforming the GITR antibody TRX518. KROS101 works by stabilizing the active form of GITRL, reducing suppressive T-cells while enhancing cytotoxic T cells. The presentation highlighted the compound's potential as a novel cancer therapy, particularly for melanoma and glioblastoma treatment.